Episode 3

27 min

Sep 6, 2026

‘Conditioning intensity MATTERS for allogeneic transplant’ w. C. Craddock

‘Conditioning intensity MATTERS for allogeneic transplant’ w. C. Craddock

In this episode Prof. Charles Craddock discusses the major aims of conditioning regimens prior to allogeneic stem cell transplantation and how to select proper intensity of the regimen to balance Graft versus Leukemia effect and regimen related toxicity.

Guest

Prof. Charles Craddock

Charles Craddock is Professor of Haemato-oncology at the University of Warwick and Academic Director of the Centre for Clinical Haematology at University Hospitals Birmingham. Prof. Craddock’s main research interests include the development of novel drug and transplant therapies in acute myeloid leukemia. He pioneered the development of the UK Haemato-oncology Trials Acceleration Programme and the UK stem cell transplant trials network, IMPACT.

More episodes

  • Episode 4

    29 min

    Oct 4, 2026

    ‘CAR T cells CURE and CAUSE cancer’ w. Roni Shouval

    In this episode, together with Roni Shouval, we discuss the evolution of CAR T cells and their potential for cure: what does cure actually mean? We will also touch the hot topic of their potential for causing cancer, how likely it is and what this means for patients and clinicians alike.

    Roni Shouval

  • Episode 2

    26 min

    Aug 9, 2026

    ‘MPN - does spleen size REALLY matter?’ w. Claire Harrison

    In this episode, Prof. Claire Harrison discusses the central role of the spleen in myelofibrosis - from its biology and clinical significance to its dominance as trial endpoint. The conversation explores how spleen responses relate to symptoms, survival, disease heterogeneity, and the future of endpoint selection in MPN clinical trials.

    Prof. Claire Harrison

  • Episode 1

    23 min

    Jul 12, 2026

    ‘PTCy – for ALL donors?’ w. Leo Luznik

    In this episode Prof. Leo Luznik will describe how post-transplant cyclophosphamide as effective GvHD prophylaxis was detected and used after haploidentical allogeneic transplantation and its current and future role in HLA identical sibling, as well as in matched and mismatched unrelated stem cell transplantation.

    0.5 CME Credits

    Prof. Leo Luznik